TB
15
2
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
85.7%
-0.8% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
TB Stigma in the UK: Patients Experiences and Everyday Responses
Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA
Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects
Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
Childhood Acute Illness and Nutrition Network
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers